Carl Dambkowski Sells 10,785 Shares of Apogee Therapeutics (NASDAQ:APGE) Stock

Apogee Therapeutics Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 10,785 shares of the stock in a transaction dated Wednesday, November 5th. The stock was sold at an average price of $55.07, for a total transaction of $593,929.95. Following the sale, the insider owned 282,008 shares of the company’s stock, valued at approximately $15,530,180.56. This represents a 3.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, October 1st, Carl Dambkowski sold 5,110 shares of Apogee Therapeutics stock. The shares were sold at an average price of $39.80, for a total value of $203,378.00.
• On Wednesday, September 3rd, Carl Dambkowski sold 2,725 shares of Apogee Therapeutics stock. The shares were sold at an average price of $37.87, for a total value of $103,195.75.

Apogee Therapeutics Stock Performance

Shares of APGE stock opened at $54.71 on Friday. The firm has a market cap of $2.52 billion, a P/E ratio of -13.25 and a beta of 1.50. Apogee Therapeutics Inc. has a fifty-two week low of $26.20 and a fifty-two week high of $63.50. The business’s 50 day moving average price is $45.64 and its 200-day moving average price is $41.41.

Apogee Therapeutics (NASDAQ:APGE) last announced its earnings results on Monday, August 11th. The company reported ($1.13) EPS for the quarter, missing analysts’ consensus estimates of ($1.03) by ($0.10). As a group, equities analysts predict that Apogee Therapeutics Inc. will post -3.09 EPS for the current year.

Analyst Ratings Changes

APGE has been the subject of several research analyst reports. BTIG Research reaffirmed a “buy” rating and issued a $115.00 target price on shares of Apogee Therapeutics in a research report on Thursday, October 9th. Wedbush restated an “outperform” rating and issued a $90.00 price objective on shares of Apogee Therapeutics in a report on Monday, August 11th. Royal Bank Of Canada upped their target price on Apogee Therapeutics from $60.00 to $70.00 and gave the stock an “outperform” rating in a report on Monday, November 3rd. Zacks Research cut Apogee Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 14th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Apogee Therapeutics in a research report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $96.50.

Hedge Funds Weigh In On Apogee Therapeutics

Large investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC boosted its position in shares of Apogee Therapeutics by 99.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 769 shares of the company’s stock worth $33,000 after purchasing an additional 383 shares in the last quarter. Brooklyn Investment Group bought a new stake in Apogee Therapeutics in the first quarter worth $42,000. AlphaQuest LLC bought a new position in shares of Apogee Therapeutics during the first quarter valued at $43,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Apogee Therapeutics by 18.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,779 shares of the company’s stock worth $77,000 after purchasing an additional 272 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in Apogee Therapeutics by 34.7% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,649 shares of the company’s stock worth $158,000 after purchasing an additional 941 shares in the last quarter. 79.04% of the stock is currently owned by hedge funds and other institutional investors.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.